Combination of Phentermine/Topiramate Er and Liraglutide 3 Mg for Intensive Therapy of Severe Obesity & T2Dm: A Case Series and Brief Review
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Objective: Patients with obesity and type 2 diabetes have severe obesity warranting intensive treatment. The medical treatment of obesity can use multiple medications that target different pathways. At present, these medications are used independently for the treatment of obesity, and there are scant data for using phentermine/topiramate (phen/top) and liraglutide combination. Methods: Here, we present interventional data and outcome of 3 obese, diabetic patients treated with these medications. Results: Patient A achieved net weight loss of 25.6% over a 30-month period on phen/top and liraglutide. This weight loss correlated with improvement in triglyceride levels (154 to 91 mg/dL), high-density lipoprotein (HDL) levels (40 to 44 mg/dL), and hemoglobin A1c (7.6 to 6.1% [60 to 43 mmol/mol]). On phen/top and liraglutide, patient B had weight loss of 11% over 24 months. Interestingly, this weight loss was correlated with an increase in triglyceride levels (116 to 231 mg/dL) and improvement in HDL (27 to 39 mg/dL). Prior to weight loss, patient was on 50 units of glargine twice daily, which was titrated off with improvement in hemoglobin A1c (15.1 to 6.2% [142 to 44 mmol/mol]). On phen/top and liraglutide, patient C had net weight loss of 27% at 18 months. This weight loss was correlated with triglyceride improvement (129 to 83 mg/dL) and HDL improvement (32 to 38 mg/dL). Prior to weight loss, patient was on 45 units of glargine, which was tapered off with an improved A1c (6.3 to 5.9% [45 to 41 mmol/mol]). Conclusion: The above cases highlight the potential for using multiple medications to target different areas for the treatment of obesity. Abbreviations: BMI = body mass index; FDA = Food and Drug Administration; HbA1c = hemoglobin A1c; HDL = high-density lipoprotein; LDL = low-density lipoprotein; phen/top = phentermine/topiramate; T2DM = type 2 diabetes mellitus
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A case study review of three patients with obesity and diabetes mellitus administered phentermine HCl/topiramate ER and liraglutide 3.0 mg per day suggested efficacy in weight reduction and improvement in metabolic parameters [118].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [118]
In the citing paper
“A case study review of three patients with obesity and diabetes mellitus administered phentermine HCl/topiramate ER and liraglutide 3.0 mg per day suggested efficacy in weight reduction and improvement in metabolic parameters [118].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [118]
Citations
Cites
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationBray, G. A., Kim, K. K., Wilding, J. P. H., & on behalf of the World Obesity Federation (2017) · Obesity Reviews · doi:10.1111/obr.12551 · Cited by 1,612
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
Eight-year weight losses with an intensive lifestyle intervention: The look AHEAD study
The Look AHEAD Research Group (2014) · Obesity · doi:10.1002/oby.20662 · Cited by 842
Allison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435
Mechanick, J. I., Hurley, D. L., & Garvey, W. T. (2017) · Endocrine Practice · doi:10.4158/ep161688.ps · Cited by 320
Aronne, L. J., Wadden, T. A., Peterson, C., Winslow, D., Odeh, S., & Gadde, K. M. (2013) · Obesity · doi:10.1002/oby.20584 · Cited by 274
Garvey, W. T., Ryan, D. H., Henry, R., Bohannon, N. J. V., Toplak, H., Schwiers, M., Troupin, B., & Day, W. W. (2014) · Diabetes Care · doi:10.2337/dc13-1518 · Cited by 215
Guo, F., Moellering, D. R., & Garvey, W. T. (2014) · Obesity · doi:10.1002/oby.20585 · Cited by 202
Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release
Garvey, W. T., Ryan, D. H., Bohannon, N. J. V., Kushner, R. F., Rueger, M., Dvorak, R. V., & Troupin, B. (2014) · Diabetes Care · doi:10.2337/dc14-0930 · Cited by 149
Fujioka, K., O'Neil, P. M., Davies, M., Greenway, F., C.W. Lau, D., Claudius, B., Skjøth, T. V., Bjørn Jensen, C., & P.H. Wilding, J. (2016) · Obesity · doi:10.1002/oby.21629 · Cited by 131
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s007 · Cited by 117
Guo, F., & Garvey, W. T. (2017) · Diabetes Care · doi:10.2337/dc17-0088 · Cited by 37
Paravattil, B., Wilby, K. J., & Turgeon, R. D. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.02.002 · Cited by 13
Cited by
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
“A case study review of three patients with obesity and diabetes mellitus administered phentermine HCl/topiramate ER and liraglutide 3.0 mg per day suggested ef fi cacy in weight reduction and improvement in metabolic parameters [118].”
BackgroundInfluentialAlhazmi, A., & le Roux, C. W. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s637685
Metadata
- Authors
- Baloch, H. M., & Nadolsky, K.
- Affiliations
- Walter Reed National Military Medical Center (US)
- Spectrum Health (US)
- Corresponding author
- Baloch, Harris M.
- ORCID
- Nadolsky, Karl
- Venue
- AACE Clinical Case Reports
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 4
- Issue
- 6
- Pages
- e482-e486
- ISSN
- 2376-0605 (ISSN-L)
- OpenAlex
- W2854614634
- Cited by
- 1
- References
- 19
- Citations by year
- 2022: 1
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 706 d)
- Locations
- AACE Clinical Case Reports (publishedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- liraglutide, morbid obesity, type 2 diabetes, combination therapy, weight loss, glycemic control, triglycerides, HDL cholesterol, GLP-1 receptor agonists, appetite suppressants
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.